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Between 1 June 2016 and 31 May 2017, 17 European 
Union (EU) and European Economic Area countries 
reported 4,096 cases associated with a multi-country 
hepatitis A (HA) outbreak. Molecular analysis identi-
fied three co-circulating hepatitis A virus (HAV) strains 
of genotype IA: VRD_521_2016, V16–25801 and RIVM-
HAV16–090. We categorised cases as confirmed, prob-
able or possible, according to the EU outbreak case 
definitions. Confirmed cases were infected with one of 
the three outbreak strains. We investigated case char-
acteristics and strain-specific risk factors for trans-
mission. A total of 1,400 (34%) cases were confirmed; 
VRD_521_2016 and RIVM-HAV16–090 accounted for 
92% of these. Among confirmed cases with available 
epidemiological data, 92% (361/393) were unvac-
cinated, 43% (83/195) travelled to Spain during the 
incubation period and 84% (565/676) identified as 
men who have sex with men (MSM). Results depict an 
HA outbreak of multiple HAV strains, within a cross-
European population, that was particularly driven by 
transmission between non-immune MSM engaging in 
high-risk sexual behaviour. The most effective preven-
tive measure to curb this outbreak is HAV vaccination 
of MSM, supplemented by primary prevention cam-
paigns that target the MSM population and promote 
protective sexual behaviour.
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Background
Hepatitis A (HA) is an acute liver disease caused by 
the hepatitis A virus (HAV) [1]. Transmission is faecal-
oral via consumption of contaminated food or water 
or through direct person-to-person contact, including 
sexual contact (particularly oro-anal, digito-anal and 
genito-oral sex). The mean incubation period is 28 
days (range: 15–50). Laboratory diagnosis is based on 
the detection of serological (anti-HAV IgM) or molecular 
(HAV RNA) markers of acute HAV infection. Preschool 
children are usually asymptomatic; however, most 
adults experience symptoms such as fever, diarrhoea 
and acute jaundice [2]. Fulminant hepatic failure and 
death are rare (0.3% of clinical cases) [3].
Men who have sex with men (MSM) are particularly at 
risk for HAV infection [4]. Over the past two decades, 
HA outbreaks among MSM have been reported across 
Australia, Europe and North-America [5,6]. The last 
reported European HA outbreak among MSM in 2008–
09 involved a high proportion of HIV-positive MSM 
[4,6-8]. HAV and HIV infections among MSM share 
overlapping risk factors such as casual sex with mul-
tiple partners, which often involves injecting drug use 
and unprotected sexual intercourse [9]. Furthermore, 
HIV co-infection can exacerbate HAV-associated liver 
abnormalities and prolong the faecal excretion of HAV 
[10].
A safe and effective vaccine against HAV has been 
available since 1995 [11]. In low and very low ende-
micity settings such as Europe, the World Health 
Organization (WHO) recommends HAV vaccination for 
vulnerable populations such as MSM; however, vac-
cine coverage is not known [12].
Outbreak detection
Between October 2016 and January 2017, the United 
Kingdom (UK), the Netherlands and Germany signalled 
an increase in HA cases among MSM, via the European 
Union (EU) Early Warning and Response System (EWRS) 
and the Epidemic Intelligence Information System for 
Food and Waterborne Diseases and Zoonoses (EPIS-
FWD) of the European Centre for Disease Prevention 
and Control (ECDC), both of which facilitate informa-
tion sharing on outbreaks and potential health threats. 
Molecular investigations detected three distinct HAV 
genotype IA strains: VRD_521_2016, RIVM-HAV16–090 
and V16–25801. Following these alerts, 14 other EU/
EEA countries notified ECDC of HA cases among MSM. 
Table 1
Total number, attack rate and male to female ratio of hepatitis A patients notified between 1 June and 31 March, 2012–2017, 
participating European Union/European Economic Area countries
Countrya, b 
Number of hepatitis A cases 
 
(all ages)
Attack rate 
 
(all ages)c
Male:Female ratio 
 
(18–45 years)d
2012–16e (Average) 2016–17e 2012–16e (Average) 2016–17e 2012–16e (Average) 2016–17e
Austria 60 125 0.7 1.4 1.1 4.6
Belgium 148 223 1.3 2.0 1.2 4.7
Denmark 42 29 0.7 0.5 1.6 1.3
Finland 23 17 0.4 0.3 1.1 6.0
France 787 750 1.2 1.1 1.1 3.1
Germany 720 668 0.9 0.8 1.3 3.3
Greece 84 241 0.8 2.2 1.1 3.3
Italy 421 976 0.7 1.6 1.5 8.4
Ireland 22 41 0.5 0.9 1.3 0.7
Malta 2 6 0.5 1.4 1.0 1.5
The Netherlands 96 119 0.6 0.7 1.1 3.0
Portugal 19 164 0.2 1.6 1.6 9.5
Slovenia 8 11 0.4 0.5 1.7 2.0
Spain 531 2,039 1.1 4.4 1.2 7.5
Sweden 85 84 0.9 0.9 1.0 1.2
UK 265 553 0.4 0.9 1.0 4.7
MSM: men who have sex with men; UK: United Kingdom.
a A food-borne HA outbreak occurred in Denmark, Finland, Norway and Sweden in 2012/13.
b A food-borne HA outbreak occurred in Austria, England, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway and Sweden in 
2013/14.
c The 2016/17 attack rates with ≥ 2 fold increase from previous 4 years are in bold.
d The 2016/17 M:F ratios ≥ 3 are in bold.
e For all years, the period referred to is 1 June to 31 March (of the subsequent year).
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Table 2
Characteristics of confirmed hepatitis A cases by strain in multi-strain outbreak affecting predominantly MSM, 1 June 
2016–31 May 2017, participating European Union/European Economic Area countries (n = 1,400 cases)
Characteristics
RIVM-HAV16–090 V16–25801 VRD 521_2016 Total
n % a n % a n % a n % a
Total 495 35 119 9 786 56 1,400 100
Sex
Male 448 92 112 94 723 93 1,283 93
Age
Median, IQR 34 28–45 34 28–40 33 28–42 33 28–43
Age categoriesb
0–17 years 14 3 2 2 10 1 26 2
18–45 years 358 73 96 83 632 82 1,086 79
46–65 years 101 21 18 16 125 16 244 18
66+ years 15 3 0 0 7 1 22 2
Subtotal 488 100 116 100 774 100 1,378 100
MSM
Yes 239 81 41 87 284 86 564 84
HIV infection
Yes 28 42 1 20 31 45 60 43
Hospitalisation
Yes 195 57 39 46 195 52 429 54
Reporting countryb
Austria 24 92 1 4 1 4 26 100
Belgium 31 74 1 2 10 24 42 100
Denmark 0 0 1 33 2 67 3 100
Finland 1 13 1 13 6 75 8 100
France 113 38 8 3 173 59 294 100
Germany 26 27 41 42 31 32 98 100
Greece 0 0 2 50 2 50 4 100
Ireland 1 14 0 0 6 86 7 100
Italy 45 26 5 3 125 71 175 100
The Netherlands 46 49 8 9 39 42 93 100
Norway 0 0 0 0 1 100 1 100
Portugal 1 1 0 0 108 99 109 100
Slovenia 3 75 0 0 1 25 4 100
Spain 27 10 12 5 223 85 262 100
Sweden 9 82 0 0 2 18 11 100
UK 168 65 39 15 56 21 263 100
Subtotal 495 NA 119 NA 786 NA 1,400 NA
Travel historyb
Yes 100 31 24 30 71 19 195 25
Country of travel
Spain 35 35 11 46 37 52 83 43
Germany 11 11 2 8 3 4 16 8
Belgium 6 6 0 0 2 3 8 4
Portugal 3 3 1 4 4 6 8 4
Italy 1 1 1 4 5 7 7 4
Other: EU 14 14 3 13 8 11 25 13
Other: non-EU 22 22 3 13 9 13 34 17
Multiple EU 8 8 5 21 7 10 20 10
Multiple EU/non-EU 4 4 0 0 4 6 8 4
Subtotal 104 NA 26 NA 79 NA 209 NA
EU: European Union; IQR: interquartile range; MSM: men who have sex with men; NA: not applicable; UK: United Kingdom.
a All percentages are based on the total of available data for each variable.
b P values < 0.05.
P values are based on comparison between the three HAV strains using the chi-squared test for categorical variables and the Kruskal-Wallis 
test for continuous variables.
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ECDC convened a multistate outbreak investigation 
team in December 2016.
We report on this Europe-wide investigation of a multi-
strain HA outbreak to describe its extent and its char-
acteristics within affected EU/EEA countries and to 
identify strain-specific risk factors associated with 
transmission.
 
Methods
Study design
All European countries affected by this outbreak were 
invited to contribute to the multistate outbreak inves-
tigation consisting of a descriptive study and a case–
case study.
Descriptive study
We conducted a retrospective descriptive study with 
the aim to describe characteristics of the population 
affected based on country-specific HA attack rates 
(AR) and male-to-female (M:F) ratios for a fixed period 
in each year, from 2012 to 2017. We used M:F ratios as 
indicators of MSM-associated epidemics where data on 
sexual orientation was not available [13]. MSM-status 
was defined as self-identifying as MSM or reporting 
sexual contact with another man. We also described 
the characteristics of confirmed, probable and possi-
ble outbreak cases notified between 1 June 2016 and 
31 May 2017. Results are presented as percentages of 
cases with available information.
Case–case study
The case–case study aimed to test the hypothesis that 
cases infected with any of the outbreak strains differed 
in exposures related to sexual transmission, including 
sexual practices, travel history and use of dating apps.
European outbreak case definition
Outbreak cases were laboratory-confirmed HAV infec-
tions in EU/EEA residents, with a date of symptom 
onset (or sample date, where missing) between 1 June 
2016 and 31 May 2017. The exposure period for defin-
ing probable and possible cases was 8 weeks before 
symptom onset or sample date.
Confirmed cases were those with a minimum sequence 
length of 300 nucleotides (nt) that was at least 99.3% 
homologous to one of the three outbreak strains based 
on overlapping fragments at the VP1–2A region. Cases 
epidemiologically linked to non-outbreak strain cases 
(<  99.3% homology) were excluded. The case defini-
tion was applied at country level and the number of 
excluded cases has not been collected.
Case definitions for probable and possible cases are 
included in Supplement 1.
Data collection
HA is a notifiable disease in all participating EU/EEA 
countries. Local public health departments investi-
gated HA cases for demographic, clinical and exposure 
characteristics, then reported to national surveillance 
systems. For all countries data from mandatory notifi-
cations was used and assumed to be comprehensive 
at the national level. Reporting practices were similar 
across countries and had not changed since 2015.
For the descriptive study, we asked national focal 
points for hepatitis A to provide aggregated numbers 
of all HA cases, by sex and age group, reported from 
1 June to 31 March between 2012 and 2017 (used for 
AR and M:F ratio calculation). National focal points 
were also asked to complete a line list of all confirmed, 
probable and possible cases; information on criteria 
for meeting case definition, onset date, sex, age, travel 
history, hospitalisation, vaccination, HIV status and 
MSM status was also requested. In addition, we col-
lected information on national HAV vaccination guide-
lines targeted to MSM and HIV-positive individuals.
For the case–case study, we compared the three out-
break strains for cases reported from July 2016 to May 
2017. We developed a standardised European question-
naire, adapted from the Public Health England (PHE) 
enhanced surveillance form [14] to collect information 
on the number of sexual partners, visiting and/or hav-
ing sex in gay venues and travel history during the 8 
weeks preceding symptoms onset. Information on con-
dom use, HIV co-infection and use of HIV-pre-exposure 
prophylaxis (PrEP) was also collected. Countries were 
asked to complete the questionnaire for confirmed out-
break cases who agreed to provide information. The 
Figure 1
Confirmed hepatitis A cases by strain and date 
of reporting in multi-strain outbreak affecting 
predominantly MSM, 1 June 2016–31 May 2017, 
participating European Union/European Economic Area 
countries, (n = 1,386 cases)
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European questionnaire was implemented in Belgium, 
Denmark, Greece, Italy and the UK (with the exception 
of England). England used the earlier PHE version and 
the Netherlands used a similar questionnaire, also 
adapted from the PHE questionnaire.
Virological analysis
HAV was confirmed through detection of anti-HAV IgM 
or by PCR identification of HAV RNA in local labora-
tories, followed by sequencing in national reference 
laboratories. The sampling strategy for sequencing 
differed across countries; most participating coun-
tries sequenced a subset of samples from notified 
cases, with only a few countries routinely sequencing 
all samples from confirmed notified cases (Denmark, 
Finland, Ireland, the Netherlands and the UK). Norway 
sequenced all outbreak-associated samples; Malta did 
not have sequencing capacity.
Sequencing of the VP1–2a region was performed 
according to national protocols, and followed by 
comparison to the reference sequences of each of 
the three outbreak strains [15-17]; 93% of sequences 
were ≥ 400 nt.
Statistical analysis
We calculated country-specific attack rates per 
100,000 residents. Population data were extracted 
from Eurostat [18]. We also calculated the M:F ratio for 
HA cases aged 18–45 years.
Categorical variables were compared using the chi-
squared test. Continuous variables were expressed 
as median with the corresponding interquartile (IQR) 
range and were compared using the Kruskal-Wallis 
test. P values of  <  0.05 were considered statistically 
significant.
We developed four logistic regression models to detect 
associations between exposure variables and specific 
outbreak strains. Model-1 compared VRD_521_2016 to 
RIVM-HAV16–090, model-2 compared VRD_521_2016 
to V16–25801, model-3 compared RIVM-HAV16–090 
Figure 2
Confirmed hepatitis A cases by strain and geographical distribution in multi-strain outbreak affecting predominantly MSM, 
1 June 2016–31 May 2017, participating European Union/European Economic Area countries (n = 1,400 cases)
 
 
Number of cases
1
10
100
Outbreak strain
Not reporting cases
V16-25801
RIVM-HAV16-090
VRD_521_2016
EU/EEA members
Other countries
Map produced on 17 January 2018. Administrative boundaries: ©EuroGraphics, ©UN-FAO.
6 www.eurosurveillance.org
to V16–25801 and model-4 compared the RIVM-
HAV16–090/V16–25801 combination (grouped due 
to having similar geographical distributions) to 
VRD_521_2016. All models included age, vaccination 
status, number of sexual partners, travel abroad and 
use of dating apps. Since all four regression models 
provided similar results, we only reported odds ratios 
(OR) and 95% confidence interval (CI) obtained from 
model-4.
Case mapping by country of reporting was done using 
ArcGIS Desktop software.
Results
Seventeen countries contributed data for the outbreak 
investigation: Austria, Belgium, Denmark, Finland, 
France, Germany, Greece, Ireland, Italy, Malta, the 
Netherlands, Norway, Portugal, Slovenia, Spain, 
Sweden and the UK (England, Wales, Northern Ireland 
and Scotland). A total of 4,096 outbreak cases were 
reported (1,400 confirmed, 964 probable and 1,732 
possible).
Descriptive study
Aggregated data
All countries except Norway provided aggregated data. 
Between 1 June 2016 and 31 March 2017, the national 
incidence of HA more than doubled in Austria, Greece, 
Italy, Malta, Portugal, Spain and the UK, compared with 
the same period during the previous 4 years. For 11 of 
the 16 countries, the M:F ratio was at least 3.0 (range: 
Table 3
Characteristics of hepatitis A cases by case classification in multi-strain outbreak affecting predominantly MSM, 1 June 
2016–31 May 2017, participating European Union/European Economic Area countries (n = 4,096)
Characteristics
Confirmed Probable Possible Total
n % a n % a n % a n % a
Total 1,400 34 964 24 1,732 42 4,096 100
Sex
Male 1,283 93 964 100b 1,732 100b 3,979 98
Age
Median (IQR) 33 28–43 33 27–40 32 26–38 32 27–40
Age categories
0–17 years 26 2 4 0 NA NA 30 1
18–45 years 1,086 79 857 89 1,732 100b 3,675 90
46–65 years 244 18 106 11 NA NA 350 8
66+ years 22 1 1 0 NA NA 23 1
Subtotal 1,378 100 963 100 1,732 100 4,073 100
Reporting country
Austria 26 2 NA NA 53 3 79 2
Belgium 42 3 36 4 40 2 118 3
Denmark 3 0 4 0 NA NA 7 0
Finland 8 1 NA NA NA NA 8 0
France 294 21 NA NA NA NA 294 7
Germany 98 7 NA NA NA NA 98 2
Greece 4 0 23 2 15 1 42 1
Ireland 7 1 5 1 NA NA 12 0
Italy 175 13 343 36 279 16 797 19
Malta NA NA 7 1 2 0 9 0
The Netherlands 93 7 10 1 13 1 116 3
Norway 1 0 NA NA NA NA 1 0
Portugal 109 8 NA NA NA NA 109 3
Slovenia 4 0 NA NA NA NA 4 0
Spain 262 19 536 56 1,330 77 2,128 52
Sweden 11 1 NA NA NA NA 11 0
UK 263 19 NA NA NA NA 263 6
Subtotal 1,400 100 964 100 1,732 100 4,096 100
NA: not applicable.
a All percentages are based on the total of available data for each variable.
b As per outbreak case definition.
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Table 4a
Characteristics and exposures of hepatitis A cases during the 8 weeks preceding symptoms onset in multi-strain outbreak 
affecting predominantly MSM, 1 June 2016–31 May 2017, participating European Union/European Economic Area countries 
(n = 308)
Characteristics
RIVM-HAV16-090 V16-25801 VRD 521_2016 Not-sequenced Total
n % a n % a n % a n % a n % a
Total 166 54 39 13 86 28 17 5 308 100
Sex
Male 155 95 38 97 79 92 17 100 289 94
Age categories
0–17 years 7 4 0 0 0 0 1 6 8 3
18–45 years 137 83 36 92 66 77 15 88 254 82
46–65 years 21 13 3 8 18 21 1 6 43 14
66 + years 1 1 0 0 2 2 0 0 3 1
Subtotal 166 100 39 100 86 100 17 100 308 100
Sexual contactb
With male 119 96 27 90 49 75 27 90 212 90
With female 4 3 3 10 6 9 3 10 13 6
With both 0 0 0 0 3 5 0 0 3 1
No sexual exposure 1 1 0 0 7 11 0 0 8 3
Subtotal 124 100 30 100 65 100 30 100 236 100
No of sexual contacts
1–2 77 70 14 50 32 63 4 40 127 64
≥ 3 33 30 14 50 19 37 6 60 72 36
Subtotal 110 100 28 100 51 100 10 100 199 100
Regular sex partnersc
1–2 50 96 13 81 22 100 4 100 89 95
3–5 2 4 2 13 0 0 0 0 4 4
6–10 0 0 1 6 0 0 0 0 1 1
> 10 0 0 0 0 0 0 0 0 0 0
Subtotal 52 100 16 100 22 100 4 100 94 100
Casual sex partnersc
1–2 34 65 9 75 11 52 6 86 60 65
3–5 12 23 1 8 8 38 1 14 22 24
6–10 3 6 1 8 2 10 0 0 6 7
> 10 3 6 1 8 0 0 0 0 4 4
Subtotal 52 100 12 100 21 100 7 100 92 100
Anonymous sex partnersc
1–2 24 60 4 33 8 47 0 0 36 48
3–5 9 23 3 25 8 47 2 33 22 29
6–10 3 8 3 25 0 0 2 33 8 11
> 10 4 10 2 17 1 6 2 33 9 12
Subtotal 40 100 12 100 17 100 6 100 75 100
Condom use
Always 28 36 8 36 13 54 2 20 51 38
Most time (> 50%) 12 16 0 0 1 4 6 60 19 14
Sometime (< 50%) 18 23 6 27 4 17 1 10 29 22
Never 19 25 8 36 6 25 1 10 34 26
PrEP: pre-exposure prophylaxis; UK: United Kingdom.
a Percentages are based on the total of available data for each variable.
b P values < 0.05.
c There is a slight difference in totals for type of sex partners (regular, casual and anonymous) as the first question on how many sex partners 
the patient has had is independent from the other questions on the number by type of sex partners.
P-values are based on comparison between the three HAV strains using the chi-squared test.
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0.7–9.5) during the outbreak period. Spain was the 
most affected country with an attack rate of 4.4 cases 
per 100,000 population (a fourfold increase from the 
previous 4 years) and a M:F ratio of 7.5 (Table 1).
Confirmed cases
In total, 1,400 confirmed cases were reported across 
all countries except Malta. The number of confirmed 
cases per country ranged between 1 and 294. The com-
pleteness of variables varied considerably; 1,382/1,400 
cases (99%) had information on sex, compared with 
140/1,400 (10%) for HIV status.
Ninety-three percent (n = 1,283/1,382) were male, 79% 
(n = 1,086/1,378) were aged between 18 and 45 years 
and 54% (n  =  429/797) were hospitalised. Forty-three 
percent (n = 60/140) with responses or 4.3% of all con-
firmed cases were reported as HIV-positive (Table 2).
The proportion of hospitalisations did not significantly 
differ between HIV-positive and HIV-negative cases 
(45%  vs  55%, p  =  0.89). Among male cases, 84% 
(n = 565/676) were MSM and 49% (n = 50/102) of MSM 
with known HIV status were HIV-positive. Non-MSM 
cases (n  =  159) did not significantly differ from MSM 
cases regarding travel history (p = 0.47).
Ninety-two percent (n = 361/393) of cases were unvac-
cinated. Of the remaining cases (n  =  32), eight had 
received only one dose of hepatitis A vaccine (three 
cases received it 2 weeks before symptoms onset), 
three cases had received two doses (two were HIV-
positive patients) and the remaining 21 lacked infor-
mation on the number of doses received. A quarter of 
confirmed cases (n  =  195/782) travelled outside the 
reporting country during the incubation period, with 
Spain being the most visited country (n = 83; 43%).
Characteristics
RIVM-HAV16-090 V16-25801 VRD 521_2016 Not-sequenced Total
n % a n % a n % a n % a n % a
Subtotal 77 100 22 100 24 100 10 100 133 100
Use of dating apps to meet sex partners
Yes 35 31 5 24 13 26 5 50 58 30
Attended a gay club
Yes 35 97 9 90 8 80 8 100 60 94
Attended a gay sauna
Yes 24 100 3 75 3 75 5 100 35 95
PrEP use
Always 0 0 0 0 0 0 1 11 1 0
Sometime (< 50%) 0 0 0 0 0 0 1 11 1 0
Never 130 100 26 100 64 100 7 78 227 99
Subtotal 130 100 26 100 64 100 9 100 229 100
HIV infection
Yes 5 21 1 11 5 14 3 20 14 17
Travel abroad
Yes 39 25 10 29 25 31 10 59 84 29
Sex while abroad
Yes 16 64 4 80 11 58 8 89 39 67
Reporting country
Belgium 0 0 0 0 0 0 10 59 10 3
Denmark 0 0 0 0 1 1 0 0 1 0
Greece 0 0 2 5 2 2 0 0 4 1
Italy 13 8 0 0 27 31 0 0 40 13
The Netherlands 13 8 2 5 7 8 7 41 29 9
Spain 0 0 5 13 3 3 0 0 8 3
UK 140 84 30 77 46 53 0 0 216 70
Subtotal 166 100 39 100 86 100 17 100 308 100
PrEP: pre-exposure prophylaxis; UK: United Kingdom.
a Percentages are based on the total of available data for each variable.
P-values are based on comparison between the three HAV strains using the chi-squared test.
Table 4b
Characteristics and exposures of hepatitis A cases during the 8 weeks preceding symptoms onset in multi-strain outbreak 
affecting predominantly MSM, 1 June 2016–31 May 2017, participating European Union/European Economic Area countries 
(n = 308)
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The epidemic curve indicates a sustained increase in 
confirmed case numbers until March 2017 (Figure 1). 
The most frequently reported strain was VRD_521_2016 
(n  =  786 /1,400; 56%), which was the first outbreak 
strain detected. Strain distribution varied geographi-
cally. In southwestern Europe the predominant strain 
was VRD_521_2016 (n  =  458/550; 83%). RIVM-
HAV16–090 was the main strain in central Europe and 
the UK (n  =  396/752; 53%), except in Germany where 
V16–25801 was the most prevalent (n  =  41/98; 42%) 
(Figure 2).
Case characteristics did not differ between strains 
with regards to median age (p  =  0.24), MSM status 
(p  =  0.21), HIV status (p  =  0.551) and hospitalisa-
tion (p  =  0.13). VRD_521_2016 cases, which account 
for 85% of the outbreak strains reported from Spain, 
were less likely to have travelled during the incubation 
period (p = 0.001).
Confirmed, probable and possible outbreak 
cases
Most of the 4,096 outbreak cases (including probable 
and possible cases) were reported in Spain (n = 2,128; 
52%), Italy (n  =  797; 19%) and France (n  =  294; 7%). 
Denmark, Ireland, Finland, Malta, Norway, Slovenia 
and Sweden reported fewer than 15 cases each 
(Table 3). Cases clustered in major cities like London, 
Amsterdam, Berlin, Lisbon and Vienna; countries with 
the earliest onset dates were Spain, Italy and the UK.
Case–case study
Enhanced surveillance information was reported for 
308 cases from seven countries, the UK accounting for 
70% of these (Table 4). Among cases with available 
information on the number of sexual partners, 72 (36%) 
reported sexual contacts with at least three partners 
and 39 were with anonymous partners. In the 8 weeks 
preceding illness, 51 of 133 MSM reported consistent 
condom use during sex. Of those reporting attending 
gay clubs or saunas, 13/60 and 32/35 reported sexual 
contact in these venues, respectively.
Of 308 cases, 84 reported travel abroad, of which 
26 visited Spain. Information on sexual activity was 
available for 58 cases, of which 39 reported sex while 
abroad. Of 12 cases with available information, 10 
reported attending Lesbian, Gay, Bisexual, Trans and 
Queer (LGBTQ) festivals. Of those with information on 
hospitalisation (n  =  69), 66% percent (n  =  177/269) 
were hospitalised for a median of five (IQR: 2–7) 
nights. Of 100 cases, 30% (n = 30) worked in the food 
or healthcare sector.
Of the 308 cases, 291 had sequence information 
(confirmed cases): 57% (n  =  166/291) were RIVM-
HAV16–090, 30% (n  =  86/291) VRD_521_2016 and 
13% (n  =  39/291) V16–25801. Of these 291 cases, 
44% (n  =  129/291) had complete information on key 
exposures and were included in the regression analy-
sis. Taking age and vaccination status into account, 
RIVM-HAV16–090 or V16–25801 cases did not statis-
tically differ from VRD_521_2016 cases (reference) in 
terms of having ≥ 3 sexual partners (OR: 0.56; 95% CI: 
0.23–1.36), travelling abroad (OR: 0.69; 95% CI: 0.28–
1.69) and using dating apps for sexual encounters (OR: 
1.55; 95% CI: 0.62–3.89) during the incubation period.
National vaccination guidelines
Fourteen countries (Belgium, Denmark, Finland, France, 
Germany, Greece, Ireland, Italy, the Netherlands, 
Portugal, Slovenia, Spain, Sweden and the UK) pro-
vided data on their national vaccination guidelines, 
which differed across countries. All countries, except 
for Sweden, recommended HAV vaccination for MSM; 
in Finland, the Netherlands and Portugal, this rec-
ommendation only took effect during the outbreak 
described here. In the UK, the recommendation was 
restricted to times and places where transmission is 
high, but was extended during the current outbreak 
to all MSM attending sexual health services. Germany, 
Greece, Slovenia and the UK recommended HAV vac-
cination for HIV-positive individuals. Vaccination was 
free for MSM except in Belgium, Denmark, France and 
the Netherlands.
Discussion
We document a large HA outbreak, with 1,400 con-
firmed cases infected with one of three identified out-
break strains and almost exclusively detected among 
young adult males. In total, there were 1,283 male 
cases with 676 (53%) providing information on sexual 
preference, of these 84% identified as MSM. Strain 
VRD_521_2016 was the first to be reported [15] and 
remains the most prevalent, particularly in southern 
Europe.
Strain evolution in HAV is very slow; the frequency of 
single nucleotide variants is generally low and propor-
tional to the number of infections. In this outbreak, we 
observed three main variants of the outbreak strains: 
two with one nucleotide difference and one with two 
nucleotides difference (data not shown). This indicates 
repeated transmission during the outbreak, which is 
expected considering that it has been active for over a 
year. Double nucleotide variants were found mainly in 
the VRD_521_2016 strain.
As MSM were particularly affected by this outbreak, 
we estimated the likely scale of transmission among 
this group by defining probable and possible outbreak 
cases. Since June 2016 there have been over 4,000 
cases reported in 17 EU/EEA countries linked to the 
current outbreak. Spain was the most affected country, 
accounting for over half of reported cases. Confirmed 
cases decreased after March 2017, but this was more 
likely attributable to a lag in the reporting of typing 
data than an indication of a change in the outbreak 
evolution.
The outbreak is ongoing as of March 2018 and, given 
that MSM appear to be disproportionately affected, it 
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is possible that further transmission events may occur 
during summer Pride events across Europe in 2018 [19].
Although the strain distribution varied over time and 
country, we found no differences in exposures and 
demographic characteristics. It is thought that this out-
break could be driven by multiple introductions and 
prolonged transmission of HAV strains originating from 
different parts of the world, including Central America 
(VRD_521_2016) and Pacific-Asia (RIVM-HAV16-090). 
Reports of these strains in Canada (personal com-
munication Meghan Hamel, Public Health Agency of 
Canada, July 2017), Israel, the US and Taiwan indicate 
that the outbreak also involves non-EU/EEA countries 
[16,20-22]. Between June 2016 and mid-May 2017, Chile 
also reported an increase of HA cases among MSM, but 
sequencing information was unavailable at the time 
of this study [20]. Between 1997 and 2005, closely 
related HAV strains circulated internationally, almost 
exclusively among MSM [23]. This suggests that with-
out appropriate interventions large MSM networks can 
sustain transmission of HAV.
MSM are more likely to engage in high-risk sexual 
behaviour while travelling abroad [24]. Results from 
the European Men-Who-Have-Sex-With-Men Internet 
Survey (EMIS) conducted in 2010 show that 26% of 
European MSM reported sex abroad in the previous 
year, with Spain and Germany being the most com-
mon destinations [24]. Our results, 8 years later, show 
a higher proportion of MSM reporting sex abroad 
(n = 39/58, 67%). The increased incidence of HA within 
vulnerable and highly interconnected subgroups of 
MSM, along with the accumulation of susceptible indi-
viduals during the period between large outbreaks, 
are likely to fuel the rapid international spread of HAV 
through sexual transmission.
We found that a high proportion of cases engaged in 
unprotected sex with non-steady partners. Avoidance 
of faecal-oral exposure during sexual activity and 
safer sex practices (e.g. use of barrier methods) play 
an important part in the prevention of HAV and other 
sexually transmitted infections (STIs), including enteric 
STIs. It has been found previously that notifications of 
gonorrhoea, syphilis and shigellosis among MSM are 
increasing in Europe [25,26]. Similarities in age, HIV 
prevalence and geographical clustering between the 
HA cases reported in our study and men affected by 
these STIs could suggest that these infections primar-
ily circulate within the same European MSM population. 
Information on STIs other than HIV was not assessed in 
this study; however, as HIV-status was poorly reported 
and numbers were small, caution is needed when inter-
preting the HIV prevalence.
As the outbreak continues to expand among MSM, 
there is an increased risk for spread to the wider popu-
lation. During and after summer 2017, several countries 
reported small food-borne outbreaks associated with 
one of the outbreak strains, with limited increases of 
HA among females, children and the elderly reported 
[19].
Although HA is generally a self-limiting disease, it can 
cause both a substantial health and economic burden 
including hospitalisation, acute hepatic failure and 
work sickness absence. In this study, over half of the 
cases with available information were hospitalised for 
approximately a week. This is likely to be an overesti-
mation, however, as there is a higher case ascertain-
ment in hospitalised cases.
In the EU/EEA, decreased HAV circulation in the last 
decades has resulted in a large fraction of the popula-
tion having no immunity triggered by natural infection, 
leaving them susceptible to contracting the infection 
[27]. HAV vaccination can compensate for this immu-
nity gap by protecting susceptible individuals. Due to 
the extent of this outbreak, it could be hypothesised 
that HAV vaccine coverage among MSM is low despite 
being recommended by WHO and ECDC [12,27,28]; of 
the 17 affected countries in our study, only four recom-
mended HAV vaccination for HIV-positive populations. 
Improving the uptake of HA vaccination within suscep-
tible MSM and HIV-positive individuals could avoid 
protracted transmission within and from these groups 
[29]. However, during the outbreak, a global shortage of 
HA vaccine has affected several EU countries (Austria, 
Denmark, France, Italy, Portugal, Spain, Sweden and 
the UK) and this may have hampered vaccine delivery.
A limitation in this study is the potential underestima-
tion of the extent of the outbreak, as only symptomatic 
individuals who sought care were reported. Confirmed 
cases were only those with the three strains originally 
reported, thus excluding other HAV strains potentially 
circulating among MSM. As of September 2017, the cir-
culation of non-outbreak strains among MSM has only 
been reported in five cases (data not shown). Some var-
iation of the outbreak strains may have been missed, 
given that sequence information was only limited to a 
small part of the genome. Moreover, sequencing capac-
ity varied between countries, with Belgium, France, 
Italy, Portugal and Spain, only sequencing a proportion 
of cases (data not shown) and other European coun-
tries lacking sequencing capacity altogether. Since the 
definition of probable and possible cases was mostly 
applicable to adult males, cases in females or children 
may have been missed during the outbreak. The low 
completeness of some variables may have biased our 
estimates, particularly for MSM and HIV status, which 
are not routinely recorded in many countries. We also 
lacked comparative information from a control group.
The case–case design may have resulted in an under-
estimation of the odds ratios since cases used as 
controls may not accurately reflect the source popu-
lation and the completeness of information related 
to the main variable of interest was suboptimal. 
Furthermore, a disproportionate number of cases with 
exposure information were from the UK and may not 
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be generalisable to all outbreak cases. However, the 
similarities in exposures from the three strains support 
the common public health recommendations applied 
across affected countries.
The HA vaccine is a safe, effective and affordable pre-
ventive measure against HA in EU/EEA countries, and 
routine targeted HAV vaccination is generally recom-
mended for MSM [27,28] (Supplement 2). However, a 
global vaccine shortage may have hampered the wide 
administration of the HA vaccine to MSM, which should 
be given priority when dealing with the vaccine short-
age, especially during an outbreak. In order to mitigate 
the effect of the shortage, some authorities have also 
endorsed the off-label use of vaccination (e.g. adminis-
tration of paediatric formulation vaccine to adults) [30].
Countries should also consider provision of post-expo-
sure prophylaxis to identified sexual and other close 
contacts of HA cases, as well as delivery of messages 
to raise awareness among MSM on how unprotected 
sex increases the risk of STIs, including HA and HIV, 
and the importance of regular testing to prevent fur-
ther transmission. The popularity of LGBTQ festivals 
provides excellent opportunities to deliver such mes-
sages. Given that many cases are at high risk for other 
STIs, testing for concurrent STIs (including HIV) should 
also be promoted.
Countries should also assess whether there is a need 
to enhance HA surveillance to ensure timely case 
detection and monitoring of this outbreak, such as 
its spread to other risk groups or the general popula-
tion. So far, no outbreak-associated deaths have been 
reported, however the quality of outcome monitoring is 
likely sub-optimal.
Conclusion
Our results suggest that a combination of interna-
tional travel and sexual networks can sustain a large 
outbreak of HAV, with multiple virus strains, within 
a susceptible population. Our findings highlight the 
importance of recording sexual history and HIV status 
when investigating male HA patients.
The inclusion of molecular characterisation in the 
outbreak case definition enabled the linking of cases 
occurring at different times and geographical locations; 
thus demonstrating the added value of utilising molec-
ular epidemiology. Since the joint investigation of the 
2013–14 EU/EEA food-borne HA outbreak, the harmoni-
sation of HAV sequencing according to the HAVnet pro-
tocol has facilitated data comparison among European 
laboratories. Typical measures for preventing most STIs 
(e.g. condom use or personal hygiene instructions) are 
not sufficient to prevent HA transmission altogether, 
but are nonetheless an important part of information 
campaigns for MSM with high-risk sexual behaviour. 
Furthermore, a safe and effective vaccine exists, and 
its use is recommended to prevent further transmis-
sion and future outbreak.
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